Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN1908-1909 for prevention of cat allergen challenge-induced early asthmatic response
2018-002477-22Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2018
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic asthma and cat allergy comparing REGN1908-1909 with Placebo (2 arms). Primary endpoint: Time to Early Asthmatic Response upon Controlled Cat Allergen Challenge in an Environmental Exposure Unit. Started Sep 2018; status: completed.
02
Drugs
REGN1908-1909
03
Conditions
allergic asthmacat allergy
Beyond the preview
Go deeper on 2018-002477-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002477-22.